Menu
Search
|

Menu

Close
X

Cellectar Biosciences Inc CLRB.OQ (NASDAQ Stock Exchange Capital Market)

1.17 USD
-- (--)
As of Feb 21
chart
Previous Close 1.17
Open --
Volume --
3m Avg Volume 42,803
Today’s High --
Today’s Low --
52 Week High 3.06
52 Week Low 1.07
Shares Outstanding (mil) 15.81
Market Capitalization (mil) 18.50
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.730
FY16
-0.353
FY15
-7.416
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
--
8.67
Price to Book (MRQ)
vs sector
2.08
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
0.08
15.38
LT Debt to Equity (MRQ)
vs sector
0.04
12.01
Return on Investment (TTM)
vs sector
-154.64
13.57
Return on Equity (TTM)
vs sector
-157.67
15.19

EXECUTIVE LEADERSHIP

Stephen Hill
Chairman of the Board, Since 2007
Salary: --
Bonus: --
James Caruso
President, Chief Executive Officer, Director, Since 2015
Salary: $204,545.00
Bonus: --
John Hamill
Interim Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Cameron Szakacs
Vice President - Clinical Development, Since 2014
Salary: --
Bonus: --
Jarrod Longcor
Chief Business Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

3301 Agriculture Dr
MADISON   WI   53716-4133

Phone: +1608.4418120

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

SPONSORED STORIES